본문바로가기

Company Overview

Company Overview

SK바이오사이언스
SK bioscience Official Website

SK bioscience is a specialized vaccine and biopharmaceutical company that was established on July 1, 2018, through a spin-off based on the accumulated capabilities of SK chemicals' vaccine business unit. Under the mission of ‘Promoting human health, from prevention to cure’, SK bioscience has built its own vaccine portfolio and continuously pursued global projects. During the COVID-19 pandemic, the Company successfully responded with a two-track strategy of global vaccine C(D)MO services and in-house vaccine development, establishing a high level of expertise and a robust network in the vaccine field.

In 2024, our next-generation pneumococcal vaccine, which is being co-developed with Sanofi, began its preparation to enter Phase III clinical trials globally, and we acquired IDT Biologika, a German vaccine and biopharmaceutical production company, to secure a production base in Europe and further strengthen our global C(D)MO business capabilities. In addition, our typhoid conjugate vaccine, SKYTyphoid, received prequalification (PQ) certification from the World Health Organization (WHO), further enhancing our competitiveness in the global health market.

SK바이오사이언스 주식회사 사업내용, 주소, 입직원수, 재무성과 표
Name SK bioscience Co., Ltd.
Business Areas R&D, production, and sales of vaccines and biopharmaceuticals
Business Sites Pangyo Headquarters and R&D Center, Andong L HOUSE
Subsidiaries SK bioscience USA Inc., IDT Biologika GmbH
Homepage www.skbioscience.com
No. of Employees 1,028
Financial Performance1)
  • Revenue : KRW 267.5 billion
  • Operating Loss : KRW 138.4 billion
  • Net Loss : KRW 50.1 billion
  • 1)As of December 31, 2024

Our Business

자체 백신 개발 및 생산, 해외 공동 개발 및 기술 이전, 해외 CMO·CDMO 위탁 개발 및 생산, 국내 사업 세부내용
Category Detail
In-house Vaccine Development and Manufacturing
  • R&D of in-house vaccines, such as COVID-19 vaccine, in collaboration with global organizations and companies based on our own technological capabilities
  • Mass production of vaccines at Andong L HOUSE, a global-level vaccine manufacturing plant
Global Co-development and Technology Transfer
  • Joint development and technology transfer throughout the entire process, from candidate discovery through clinical trials, licensing, and sales
    • Rapid delivery of product development solutions
    • Open innovation with global partners
Global CMO·CDMO Business
  • Joint vaccine research and vaccine C(D)MO business with global companies/organizations based on our diverse platform development experience, technological prowess, and flexible production system
Domestic Business
  • Joint sales and C(D)MO business with domestic/foreign companies to improve the convenience of vaccine recipients and expand the domestic vaccine market based on our sales capabilities and marketing infrastructure

Major Products

SK bioscience is a leading vaccine company that emerged as a spin-off from SK chemicals in 2018. Prior to the spin-off, SK bioscience selected premium vaccines with high-added value as its primary growth engine. Since then, it has continuously made development efforts, successfully creating Korea’s first trivalent cell culture influenza vaccine in 2015, a quadrivalent cell culture influenza vaccine in 2016, a zoster vaccine in 2017, a varicella vaccine in 2018, and the first homegrown Covid-19 Vaccine SKYCovione in 2022. In addition to premium vaccines, SK bioscience has secured a new pipeline and platform technologies in the fields of basic and therapeutic vaccines. Simultaneously, while expanding its business into biopharmaceuticals, it has established a plan to become a major global vaccine and bio-company.

  • SKYCellflu Trivalent
    (Cell-culture-derived influenza vaccine)

    세포배양 인플루엔자 3가 백신 (스카이셀플루 3가)

    In 2015, SKYCellflu Trivalent was the first cell culture-based influenza vaccine developed in South Korea.

    It is manufactured in bioreactors without any antibiotics or preservatives, unlike fertile chicken eggs which can be dangerous for people with allergies.

    As a cell culture-based vaccine, it acquired the first World Health Organization Pre-Qualification (PQ) certification.

  • SkyZoster Inj.
    (Herpes zoster live attenuated vaccine)

    대상포진 백신 (스카이조스터)

    The world’s second and South Korea’s first shingles vaccine (herpes zoster), SKYZoster Inj. is a premium vaccine.

    The vaccine is a live attenuated varicella-zoster virus, which has been rigorously proven safe by specialized non-clinical trial institutes, and provided to various countries.

    After its launch, the vaccine has become a leading product in meeting the rising demand for herpes zoster treatments.

  • SKYCovione Multi Inj.
    (Recombinant protein vaccine for COVID-19)

    합성항원 방식 코로나19 백신 (스카이코비원)

    SKYCovione is South Korea's first developed synthetic antigen COVID-19 vaccine.

    The synthetic antigen vaccine platform has a long history of safety and efficacy in existing vaccines, including influenza (flu), hepatitis B, and cervical cancer.

    Additionally, these vaccines can be stored under refrigerated conditions of 2 to 8 degrees Celsius, allowing them to be distributed using the existing vaccine logistics network without the need for thawing or other processes during the administration stage.

  • SKYCellflu Quadrivalent
    (Cell-culture-based influenza vaccine)

    세포배양 인플루엔자 표면항원 백신 (스카이셀플루 4가)

    SKYCellflu Quadrivalent is South Korea’s only and the world’s first cell culture-based quadrivalent influenza vaccine.

    Same with SKYCellflu Trivalent, it is manufactured in bioreactors without any antibiotics or preservatives which shortens the production period by 2-3 months and secures production stability comparing to the conventional technique of using fertile chicken eggs.

    Based on the WHO Pre-Qualification (PQ), its innovation and reliability have garnered high market shares domestically and globally.

  • SKYVaricella Inj.
    (Live Varicella Virus Vaccine)

    수두생바이러스 백신 (스카이바리셀라)

    A chickenpox vaccine, SKYVaricella Inj. was developed with our own bioprocess technology.

    Its immunogenicity and safety have been confirmed in a global phase 3 clinical trial conducted in children at 19 domestic and foreign clinical institutions.

    It received the world's second WHO PQ certification and won the bid for export to Latin America from the Pan American Health Organization (PAHO), an international United Nations organization.

  • SKYTyphoid Multi Inj.
    (Typhoid conjugate vaccine, for export)

    장티푸스 백신 (스카이타이포이드)

    SKYTyphoid Multi Inj. is a polysaccharide-protein conjugate vaccine developed by conjugating the polysaccharide of typhoid bacteria, which acts as the antigen, to the diphtheria toxin protein (diphtheria toxoid), which acts as a carrier.

    Since 2013, SK bioscience jointly developed the vaccine with the International Vaccine Institute (IVI) and Bill & Melinda Gates Foundation. After the completion of development in 2022, we have even obtained a export item license.

    It offers higher immunogenicity with a single dose and provides longer-term prevention, thus inoculation for infants and toddlers exposed to poor environment lacking clean water can be effective.